PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE der the Paperwork Reduction Act of 1995, no persons are required to res

Substitute for form 1449/PTO

Sheet

TO PARE

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/580,962		
Filing Date	May 31, 2006		
First Named Inventor	Erik Buntinx		
Art Unit	1617		
Examiner Name	Ramachandran, Umamaheswari		
Attorney Docket Number	20248/20		

				DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan
		Number-Kind Code <sup>2 (# known)</sup>			Figures Appear
	1	<sup>US-</sup> 6,358,698 B1	03-19-2002	Weiner et al.	
	2	<sup>US-</sup> 2005/0148018 A1	07-07-2005	Weiner et al.	
	3	<sup>US-</sup> 2004/0213816 A1	10-28-2004	Weiner et al.	
	4	<sup>US-</sup> 2006/0264465 A1	11-23-2006	Weiner et al.	
	5	<sup>US-</sup> 2006/0264466 A1	11-23-2006	Weiner et al.	
	6	<sup>US-</sup> 2006/0199842 A1	09-07-2006	Weiner et al.	
	7	<sup>US-</sup> 2005/0261340 A1	11-24-2005	Weiner et al.	
·····	8	<sup>US-</sup> 2005/0261278 A1	11-24-2005	Weiner et al.	
	9	<sup>US-</sup> 2005/0288328 A1	12-29-2005	Weiner et al.	
		US-			
		US-	***	·	
		US-			
		US-			8
		US-		1	
•		US-			

FOREIGN PATENT DOCUMENTS					
Examiner Cite Initials* No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear
	ļ				

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (09-06) Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE and Trademark Office; U.S. DEPARTMENT OF COMMERCE and the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/580,962 Filing Date INFORMATION DISCLOSURE May 31, 2006 STATEMENT BY APPLICANT **First Named Inventor** Erik Buntinx Art Unit 1617 (Use as many sheets as necessary) Examiner Name RAMACHANDRAN, UMAMAHESWARI Sheet Attorney Docket Number 2 2 29248/29 of

Fuenise:	Cita	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	10	www.biam2.org/www/Sub2783.html, entitled "Pipamperone Dichlorhydrate," November 12, 2000, 1-4.	
	11	www.adiph.org/pic/pedia-neuroleptiques.pdf, entitled "Medicaments Psychotropes: Posologies Chez L'Enfant et L'Adolescent," August 2001, 1-3.	
	12	HEISER P et al., entitled "The selective serotonin reuptake inhibitors and the newer antidepressants in child and adolescent psychiatry," Zeitschrift fur Kinder - und Jugendpsychiatrie und Psychotherpie Switzerland 30: 2002, 173-183.	
	13	CARLIER PR et al., "Synthesis of a Potent Wide-Spectrum Serotonin-, Norepinephrine-, Dopamine- reuptake inhibitor (SNDRI) and a species-selective dopamine reuptake inhibitor based on the gamma-amino alcohol functional group, Bioorgan. Medicin. Chem. Let. 8, 1998, 487-492.	
	14	FITZGERALD K D et al., entitled "Risperidone Augmentation of Serotonin Reuptake Inhibitor Treatment of Pediatric Obsessive Compulsive Disorder," Journal of Child and Adolescent Psychopharmacology, Vol. 9, No. 2, 1999, 115-123.	
	15	MCDOUGLE C J et al., entitled "A Double-blind. Placebo-Dontrolled Study of Risperidone Addition in Serotonin Reuptake Inhibitor-Refractory Obsessive-complusive Disorder," Arch Gen Psychiatry, Vol. 57, August 2000, 794-801.	
	16	MAINA G et al., entitled "Antipsychotic agumentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued," Int. Clin. Psychopharm, 18, 2003, 23-28.	
	17	HIROSE S et al., entitled "An Open Pilot Study Combining Risperidone and a Selective Serotonin Reuptake Inhibitor as Initial Antidepresant Therapy," J. Clin. Psych. 63, 2002, 733-736.	
	18	Truffinet P et al., Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. Am J. Psychiatry 156: 419-425, 1999.	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.